Overview

A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation

Status:
Completed
Trial end date:
2017-11-10
Target enrollment:
Participant gender:
Summary
The objective of this study is to verify the efficacy and investigate the safety of the study drug when ASP0456 is administered orally for 4 weeks and 52 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Linaclotide